
    
      The western medicine treatment for CAD not amenable to revascularization is limited. Shexiang
      Baoxin Pill, a kind of Chinese patent medicine has been used for treating coronary artery
      disease in clinical practice in China for many years.

      Shexiang baoxin pill(SBP) is applicable to "Qi deficiency and blood stasis syndrome" in
      traditional Chinese medicine. Recent experimental research has indicated that SBP can improve
      myocardial ischemia and promote therapeutic angiogenesis.
    
  